ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

Koessler, Thibaud; Alsina Maqueda, Maria; Arnold, Dirk; Ben-Aharon, Irit; Collienne, M.; Lutz, Manfred

View

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective, 2022 (324.2Kb)

Author

Koessler, Thibaud

Alsina Maqueda, Maria

Date

2022-04

Permanent link

https://hdl.handle.net/11351/8366

DOI

10.1016/j.esmoop.2022.100392

ISSN

2059-7029

WOS

000819921700001

PMID

35180656

Show full item record

Abstract

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Keywords

Neuroendocrine tumours; Pancreatic cancer; Stomach cancer

Bibliographic citation

Koessler T, Alsina M, Arnold D, Ben-Aharon I, Collienne M, Lutz MP, et al. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO Open. 2022 Apr;7(2):100392.